文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

18F-DCFPyL PET/CT再分期对复发前列腺癌 salvage 与全身治疗利用的影响

Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of 18F-DCFPyL PET/CT Restaging.
PubMed 文献 · Adv Radiat Oncol · 2020-09-09

一项前瞻性多中心临床试验评估了79例原发性放疗后复发前列腺癌患者接受PSMA靶向18F-DCFPyL PET/CT再分期的管理影响。59%的患者实际管理与PET/CT前计划管理相比发生重大改变,而PET/CT后即时问卷低估了这一比例(32%)。14%接受高剂量率近距离治疗作为局部复发的单一治疗,中位随访20个月时91%无复发。

要点

  • 59%复发前列腺癌患者因PSMA PET/CT再分期发生重大管理改变。
  • PET/CT后即时问卷低估重大改变率(32% vs 59%)。
  • 前列腺PSMA摄取活检灵敏度86%、特异度67%、阳性预测值92%。

核心结论

  • 多数复发前列腺癌患者实际管理与PSMA靶向PET/CT前计划管理相比发生重大改变,且该改变被PET/CT后问卷低估。

研究设计与样本

  • 前瞻性多中心临床试验,纳入79例原发性放疗后复发前列腺癌患者,评估18F-DCFPyL PET/CT再分期,比较PET/CT前后计划管理并与实际管理对照。

主要发现

  • 59%患者实际管理与PET/CT前计划管理相比发生重大改变,PET/CT后即时问卷报告的重大改变率为32%。
  • 18例前列腺PSMA摄取可疑恶性患者接受前列腺活检,PSMA摄取灵敏度86%、特异度67%、阳性预测值92%。

关键数值与推荐

  • 前列腺PSMA摄取预测恶性的灵敏度86%、特异度67%、阳性预测值92%。
  • 14%患者接受单纯高剂量率近距离治疗,中位随访20个月无复发率91%。

临床怎么用

  • 对原发性放疗后复发前列腺癌患者,PSMA靶向PET/CT再分期可指导salvage与全身治疗选择,实际管理改变率高于PET/CT后问卷的即时评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Our purpose was to investigate the effect of the addition of prostate-specific membrane antigen (PSMA)-targeted positron emission tomography/computed tomography (PET/CT) in patients with recurrent prostate cancer post-primary radiation therapy. METHODS AND MATERIALS: A prospective, multi-institutional clinical trial evaluated 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (18F-DCFPyL) PET/CT restaging in 79 men with recurrent prostate cancer post-primary radiation therapy. We report actual patient management and compare this with proposed management both before and after PSMA-targeted PET/CT. RESULTS: Most patients (59%) had a major change in actual management compared with pre-PET/CT proposed management. The rate of major change was underestimated by immediately post-PET/CT surveys (32%). Eighteen patients with PSMA avidity in the prostate gland suspicious for malignancy had a prostate biopsy. Sensitivity, specificity, and positive predictive values of PSMA uptake in the prostate were 86%, 67%, and 92%, respectively. Thirty percent of patients had directed salvage therapy and 41% underwent systemic therapy. Eleven out of 79 patients (14%) had high-dose-rate brachytherapy alone for local recurrence, and 91% were free of recurrence at a median follow-up of 20 months. CONCLUSIONS: Most patients had a major change in actual management compared with pre-PSMA-targeted PET/CT planned management, and this was underestimated by post-PET/CT questionnaires.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Liu W, Zukotynski K, Emmett L, et al. Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of 18F-DCFPyL PET/CT Restaging. Adv Radiat Oncol. 2020. PMID: 33521396. doi:10.1016/j.adro.2020.08.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。